关于公司2026年使用闲置募集资金 证券代码：002393 证券简称：力生制药 公告编号：2026-020 天津力生制药股份有限公司 进行现金管理额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 天津力生制药股份有限公司（以下简称"公司"或"力生制药"）为提高募集资金使用效 率，保障公司和股东利益，根据《深圳证券交易所上市公司自律监管指引第1号——主板 上市公司规范运作》《上市公司募集资金监管规则》等相关规定，拟在不影响公司募集资 金投资项目实施的情况下，使用额度不超过人民币8.74亿元及后续产生的利息、收益总额 的闲置募集资金购买安全性高、流动性好的保本型投资产品，期限不超过股东会批准之日 起12个月，在上述额度及期限范围内资金滚动使用。 该议案尚需提交公司股东会审议。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准天津力生制药股份有限公司首次公开发行股票 的批复》（证监许可［2010］371 号）文核准，公司 2010 年 4 月首次向社会公开发行人 民币普通股（A 股）4,600 万股，每股面值 1.00 元，发行价格为 45 元/股 ...

证券代码：002393 证券简称：力生制药 公告编号：2026-022 天津力生制药股份有限公司 关于公司2026年度现金管理暨关联交易额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、概述 天津力生制药股份有限公司（以下简称："公司"或"力生制药"）根据第八届董事会 第四次会议议案之九所述，为提高公司资金使用效率，合理利用自有资金，增加公司收益， 在保证公司日常经营资金需求及资金流动性、安全性前提下，公司本年拟使用闲置自有资金 人民币不超过 12 亿元分批购买投资产品。在上述额度内，资金在有效期内可以滚动使用。 公司在上述额度范围内适时购买安全性较高、流动性较好、由主要大型商业银行或证券 机构发行的投资产品。 主要购买以下投资产品： 1.风险等级不超过 R2 的理财产品； 2.证券交易所国债逆回购； 3.货币型基金； 4.结构性存款。 购买投资产品的交易对方有可能包括但不限于渤海银行股份有限公司（以下简称"渤海 银行"）及其下属子公司、渤海证券股份有限公司（以下简称"渤海证券"）及其下属子公 司（包括渤海汇金证券资产管理有限公司等）。因渤海银行 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） 承董事會命 天津發展控股有限公司 主席及執行董事 滕飛 香港，二零二六年三月十日 於本公告日期，本公司董事會包括滕飛先生 、翟欣翔博士、夏濱輝先生 、 孫利軍先生 * 、伍綺琴女士 ** 、黃紹開先生 ** 、樓家強先生 ** 及冼漢廸先生 ** 。 （股份代號：882） 海外監管公告 本公告乃天津發展控股有限公司（「本公司」）根據證券及期貨條例（香港法 例第571章）第XIVA部及香港聯合交易所有限公司證券上市規則第13.09條及 第13.10B條而作出。 本公司非全資附屬公司天津力生製藥股份有限公司（「力生製藥」）於深圳證 券交易所網站(www.szse.cn)刊發有關其二零二五年度業績快報之公告，該公告 之全文轉載於本公告附頁。 於本公告日期，本公司間接持有力生製藥約34.12%之已發行股本。 * 非執行董事 ** 獨立非執行董事 证券代码：002393 证券简称：力 ...

Revenue and Profit - The total operating revenue for 2025 reached ¥1,392,663,934.63, an increase of 4.23% compared to the previous year[5] - The total profit for 2025 was ¥456,432,176.66, reflecting a significant increase of 111.36% year-over-year, driven by market expansion and increased product sales[5] - The net profit attributable to shareholders of the listed company was ¥418,365,973.76, up 126.72% from the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥169,084,905.34, which is a 64.16% increase year-over-year[5] - Basic earnings per share increased to ¥1.62, representing a growth of 125.00% compared to the previous year[4] Financial Ratios and Returns - The weighted average return on net assets rose to 8.56%, an increase of 4.82 percentage points from the previous year[4] Assets and Equity - Total assets at the end of the reporting period were ¥5,584,429,772.98, a decrease of 3.48% from the beginning of the period[4] - The equity attributable to shareholders of the listed company decreased to ¥4,630,138,992.15, down 2.93% from the beginning of the period[4] - The net asset per share attributable to shareholders was ¥17.98, a decrease of 2.81% compared to the previous period[4] Financial Data Confirmation - The company confirmed that the disclosed financial data is within the previously announced performance forecast range, indicating no discrepancies[7]

证券代码：002393 证券简称：力生制药 公告编号：2026-012 天津力生制药股份有限公司 关于药品伏立康唑片通过上市许可申请的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、概况 近日，天津力生制药股份有限公司（以下简称"公司"）收到国家药品监督管理局颁 发的关于伏立康唑片0.2g规格的《药品注册证书》（批件编号：2026S00546）和伏立康 唑片50mg规格的《药品注册证书》（批件编号：2026S00547），上述药品通过药品上 市许可申请。 药品名称 伏立康唑片 剂 型 片剂 规 格 0.2g 50mg 注册分类 化学药品 药品生产企业 天津力生制药股份有限公司 原药品批准文号 无 申请内容 上市许可申请 受理号 CYHS2404239 CYHS2404240 审批结论 通过上市许可申请 二、该药品的基本情况 三、该药品的相关信息 伏立康唑片适应症： 本品是一种广谱的三唑类抗真菌药，适用于治疗成人和 2 岁及 2 岁以上儿童患者的 下列真菌感染： （1）侵袭性曲霉病。 （2）非中性粒细胞减少患者的念珠菌血症。 （3）对氟康唑耐药的念珠菌 ...

Core Viewpoint - Lisheng Pharmaceutical (002393) is a publicly listed company in the Shenzhen Stock Exchange, operating in the pharmaceutical manufacturing and biopharmaceutical industry, recognized as a national high-tech enterprise and a model enterprise for technological reform by the State-owned Assets Supervision and Administration Commission in 2022 [1] Company Overview - Established in 1951, the company focuses on drug research, production, and sales, with a product range covering 15 major categories and a total of 296 varieties [1] - The company holds 111 patent authorizations and 189 registered trademarks [1] Technological Capabilities - Lisheng Pharmaceutical has early investments in controlled-release formulations, with core technologies including a permeation pump controlled-release technology based on laser perforation [1] - This technology has been applied in products such as Doxazosin Mesylate Sustained-Release Tablets, enabling long-lasting and stable drug release [1] Production and R&D Facilities - The company has established a controlled-release formulation platform and is recognized as a key laboratory for controlled-release and solid dispersion drug formulations in Tianjin [1] - It possesses various formulation technologies, including skeleton-controlled release, sustained-release micro-particles, and solid dispersions, forming a comprehensive formulation technology system [1] Industry Position - Lisheng Pharmaceutical is one of the few companies in China capable of industrializing permeation pump controlled-release formulations, achieving breakthroughs in the localization of key equipment and excipients in the high-end formulation sector [1]

Core Viewpoint - The company, Qianyuan Pharmaceutical, has authorized its management to participate in a judicial auction for a 40% stake in Zhejiang Qianyuan Hailisheng Pharmaceutical, increasing its ownership to 80% after winning the bid at 155 million yuan [1] Group 1 - The company will collaborate with Zhoushan Ronghao Trading Co., Ltd. to bid for the stake [1] - The auction took place on February 25, 2026, through the Ningbo Yinzhou District People's Court's online platform [1] - The total bid amount for the 40% stake was 155 million yuan [1]

Core Viewpoint - The report highlights the growth in the chemical raw materials and products manufacturing industry in China, indicating a positive trend in the number of enterprises and overall market potential from 2026 to 2032 [1] Industry Summary - As of January to December 2025, the number of enterprises in the chemical raw materials and products manufacturing industry reached 27,102, an increase of 815 compared to the previous year, representing a year-on-year growth of 3.1% [1] - This sector accounts for 5.15% of the total industrial enterprises in China, reflecting its significance within the broader industrial landscape [1] - The report is based on data from the National Bureau of Statistics and compiled by Zhiyan Consulting, a leading industry consulting firm in China [1] Company Summary - The report mentions several listed companies in the chemical sector, including Hainan Haiyao (000566), Northeast Pharmaceutical (000597), and others, indicating a diverse range of players in the market [1] - Zhiyan Consulting provides comprehensive industry research reports, business plans, feasibility studies, and customized services, emphasizing its role in supporting investment decisions in the chemical industry [1]

Core Viewpoint - The company, Lifesun Pharmaceutical, has received approval from the National Medical Products Administration for the market entry of its raw material drug, Adenosine Phosphate, which is expected to enhance its market competitiveness and create synergy with its formulation products [1]. Group 1: Product Approval - Lifesun Pharmaceutical announced the receipt of the approval notice for the market entry of Adenosine Phosphate raw material drug [1]. - Adenosine Phosphate, previously known as Vitamin B4, is a crucial component for nucleic acids and coenzymes, participating in the synthesis of DNA and RNA [1]. - The drug is clinically used to prevent and treat leukopenia caused by various reasons, including acute granulocytopenia, particularly due to chemotherapy, radiation therapy, and benzene poisoning [1]. Group 2: Market Impact - The approval of Adenosine Phosphate is expected to facilitate industrial synergy with the company's formulation products [1]. - This development is anticipated to enhance the company's market competitiveness [1].

Overview - Tianjin Lifeng Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the listing application of Adenine Phosphate raw material [2] Product Information - The product, Adenine Phosphate, is a chemical raw material with a molecular weight of 233.12 and a molecular formula of C5H5N5·H3PO4 [2] - It is used clinically to prevent and treat leukopenia caused by various reasons, particularly in cases related to chemotherapy, radiation therapy, and benzene poisoning [2] Impact on the Company - The approval of this product's listing application is expected to enhance the company's market competitiveness by creating industrial synergy with its formulation products [3]